ORGO
NASDAQ · Biotechnology
Organogenesis Holdings Inc
$1.67
-0.74 (-30.71%)
Open$1.84
Previous Close$2.41
Day High$1.86
Day Low$1.54
52W High$7.08
52W Low$2.04
Volume—
Avg Volume690.9K
Market Cap240.62M
P/E Ratio88.50
EPS$-0.02
SectorBiotechnology
Analyst Ratings
Strong Sell
7 analysts
Price Target
+400.0% upside
Current
$1.67
$1.67
Target
$8.35
$8.35
$5.30
$8.35 avg
$10.56
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 624.10M | 579.16M | 163.70M |
| Net Income | 40.96M | 34.21M | 15.03M |
| Profit Margin | 6.6% | 6.2% | 9.2% |
| EBITDA | 66.34M | 58.48M | 20.76M |
| Free Cash Flow | — | — | 17.26M |
| Rev Growth | +7.8% | +7.8% | +17.3% |
| Debt/Equity | 0.05 | 0.05 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |